Reviews/Heart Failure Management/Primary prevention implantable cardioverter-defibrillator reduces sudden cardiac death
Icd · HFM-ICD-01 · v2
The question is whether fitting a defibrillator to prevent a first dangerous rhythm cuts sudden cardiac deaths in people with weak heart pumping. The strongest evidence here comes from one controlled analysis within a defibrillator-versus-placebo trial [6], which found the device sharply lowered sudden death in patients without diabetes but not in those with diabetes. A large real-world registry [3] points the same direction, showing lower death rates with the device in the highest-risk patients, and a device-activity study [12] shows the defibrillators do fire appropriately. The panel found the direction of benefit well supported but noted that the corpus holds only this single trial-derived analysis, no landmark primary-prevention trial, and a clear subgroup where the benefit disappears. The supporting registry data are also observational and can be skewed by which patients get devices.
The only comparator-controlled, sudden-death-endpoint evidence is the diabetes-stratified analysis of SCD-HeFT [6], in which the defibrillator reduced sudden cardiac death in non-diabetic HFrEF patients (HR 0.26, 95% CI 0.15-0.46) but not in diabetic patients (HR 0.85, 95% CI 0.52-1.40), of 1676 randomised patients of whom 540 (32%) had diabetes. Registry data [3] show that among 13 475 primary-prevention-indicated patients, only 15.5% received a device, and device use was associated with lower mortality only in those with high predicted sudden-death and lower overall-mortality risk (34% and 37% relative reductions in 3-year all-cause and cardiovascular mortality). The OBSERVO-ICD sub-analysis [12] records that 193 of 1089 recipients (17.7%) experienced appropriate ICD therapy over a median 36 months, confirming meaningful device activity but without a no-device comparator. Together the corpus supports the claim's direction while resting on a single trial-derived analysis plus confounded observational data. The contested point: The evidence divides on uniformity: [6] shows the sudden-death benefit present in non-diabetic patients but absent in diabetic patients (Pinteraction=0.002), so the blanket wording for all HFrEF with EF at or below 35% overstates consistency. It also divides on strength of design, since the only randomised signal is a single subgroup-stratified secondary analysis rather than a landmark primary-prevention trial.
All 13 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Heart Failure Management, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
No landmark primary-prevention RCT is in the corpus (no SCD-HeFT primary report, MADIT-II, DEFINITE, or DANISH). The entire randomised signal rests on a single diabetes-stratified secondary analysis [6].
The effect is not uniform: [6] found no SCD reduction in diabetic HFrEF (HR 0.85, 95% CI 0.52-1.40, ~32% of patients; Pinteraction=0.002), so the claim's blanket wording for all HFrEF EF<=35% overstates consistency.
Where it remains uncertain. The same analysis found no sudden-death reduction in diabetic patients (HR 0.85, 95% CI 0.52-1.40; Pinteraction=0.002), who were 540 of 1676 (32%) of the trial [6].
Aleatory
The sudden-death benefit is present in non-diabetic and absent in diabetic HFrEF patients within the same trial [6], so individual outcomes vary by patient subgroup.
Epistemic
The corpus holds no primary SCD-HeFT report, MADIT-II, DEFINITE or DANISH; the controlled signal comes from a single secondary analysis [6].
Inferential
[3] is observational; healthier patients may preferentially receive devices, and its endpoint is all-cause and cardiovascular mortality, not sudden-death incidence.
The load-bearing papers from a corpus of 13, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Real-world directional corroboration that ICD confers survival benefit in appropriately selected high-SCD-risk HFrEF patients.
“ICD use was associated with lower mortality only in patients with higher predicted SCD and lower mortality risk (34% and 37% relative risk reduction for 3-year all-cause and cardiovascular mortality, respectively).”
Panel auditInternal validity: medium · scope of inference: Barriers to and mortality association of primary-prevention ICD use in a Swedish HFrEF registry.Key limitations: observational, not randomized · endpoint is mortality not SCD · confounding by indication
Direct randomised (ICD vs placebo) evidence of a large, significant SCD reduction in the majority non-diabetic HFrEF population — the backbone supporting the claim.
“By contrast, ICD therapy did reduce sudden cardiac death in HFrEF patients without diabetes (HR = 0.26; 95% CI 0.15-0.46); Pinteraction=0.002.”
Panel auditInternal validity: high · scope of inference: Effect of ICD therapy on SCD in HFrEF, stratified by diabetes status.Key limitations: subgroup/post-hoc analysis by diabetes · no benefit in diabetic subgroup · single parent trial
Indirect support: devices in HFrEF recipients detect and treat arrhythmic events at a clinically meaningful rate, consistent with an SCD-prevention mechanism.
“During a median follow-up of 36 months (1st-3rd IQR 25-48 months), 193 patients (17.7%) experienced at least one appropriate ICD therapy”
Panel auditInternal validity: medium · scope of inference: Accuracy of the MAGGIC score for predicting competing non-sudden death in HFrEF ICD recipients.Key limitations: no non-ICD comparator · endpoint is non-sudden death prediction · single-arm registry
3 of 13 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
A single controlled SCD-endpoint analysis with a large significant effect supports the claim's direction, but subgroup heterogeneity, confounded observational support, and the absence of landmark trials cap confidence below Established.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Absent landmark primary-prevention RCT. The entire randomised signal rests on one diabetes-stratified secondary analysis [6]; no primary-endpoint trial is in the corpus to certify overall magnitude. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: Include or conduct a primary-prevention RCT of ICD versus control in HFrEF with EF at or below 35% reporting sudden-cardiac-death incidence as a pre-specified endpoint.
Open question: Does primary-prevention ICD reduce sudden-cardiac-death incidence across the whole HFrEF population with EF at or below 35%, not only in subgroups? Why it is still open: The only controlled analysis in the corpus [6] is stratified by diabetes and derived from one trial; no landmark primary-prevention trial is present.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19